A natural history of familial platelet disorder with myeloid malignancy; HEXIM1 as an essential transcription regulator in erythropoiesis; residual disease predicts relapse in CML patients
In this week's episode we’ll discuss the findings from a natural history study of patients with familial platelet disorder with myeloid malignancy, learn more about the role of HEXIM1 as an essential transcription regulator in human erythropoiesis, and discuss the utility of residual disease as a predictor of relapse in CML patients stopping TKI therapy.
Podden och tillhörande omslagsbild på den här sidan tillhör American Society of Hematology. Innehållet i podden är skapat av American Society of Hematology och inte av, eller tillsammans med, Poddtoppen.
